



Frost & Sullivan lauds IBA for its Technology Dominance in the European Radiopharmaceuticals Market

Saclay, April 23 2010

Based on its recent research on the radiopharmaceuticals market, Frost & Sullivan presents IBA Molecular with the “2010 European Radiopharmaceuticals Technology Leadership of the Year Award.”

This award recognises the superior commitment that IBA is showing in bringing innovative solutions to the medical community. Over the last year, IBA Molecular has developed a strong pipeline of radiopharmaceuticals which include major in-licensed tracers such as Redectane (Kidney cancer) and ML10 (Apoptosis imaging) along with generic PET and SPECT tracers. The pipeline reflects the capability of the company to deploy new technologies or ease access to insufficiently available radiopharmaceuticals.

In fact, contrary to other large players who have shown signs of divestment from the radiopharmaceutical sector, Frost and Sullivan observed that IBA has intensified its investment over the past 3 years, which included the acquisition of global player Cisbio in 2008, the complete upgrade of its SPECT manufacturing lines and the in-licensing of innovative compounds nearing the final stages of development. This resulted in IBA being uniquely able to develop, register, manufacture and distribute radiopharmaceutical innovation worldwide. Frost & Sullivan pointed that this unique positioning entitles IBA to be the primary partner of technology owners seeking to bring their agents to the market.

Frost and Sullivan salutes the relevance of the vision of IBA who is investing in the development of a strong Molecular Imaging discipline to join the personalization of medicine. In the next 5 years, IBA is expected to bring to market compounds that could significantly and massively change the management of patients subjects to cancer, neurology and cardiology diseases.

The award has been attributed following an extensive assessment of the radiopharmaceutical environment. The major players have been surveyed by Frost & Sullivan’s analysts under criteria such as: R&D spending, development of new technologies and value to customer. IBA consistently achieved superior rating on all criteria.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Molecular Imaging

Molecular imaging is an emerging field which aims to visualize non-invasively biological processes in-vivo. The ability to image disease-related biological processes may allow to detect disease early, characterize it better and to personalize treatment by real-time monitoring of its therapeutic effect. Molecular imaging depends on special molecules (probes) that can selectively target these biological processes, while carrying an imaging moiety for



visualization, such as ^{18}F or other positron emitting radio-isotopes that can be visualized by positron emission tomography (PET).

About IBA

Founded in 1986 in Louvain-la-Neuve, Belgium, IBA is primarily active in the medical industry. It develops and markets state-of-the-art equipment and radiopharmaceuticals for cancer diagnosis and treatment. In addition, it uses the scientific expertise thus gained to provide electron accelerators for industrial sterilization and ionization. *Listed on the pan-European stock exchange Euronext, IBA is included in the BEL Mid Index (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).*

Website: <http://www.iba-molecular.com>

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit <http://www.awards.frost.com>.

Contacts :

IBA Molecular

Antoine JACQUES
Marketing Director Europe
Tel: + 33 1 69 85 76 65

Frost & Sullivan

Jasmine Malone – Promotions Coordinator
Phone: +44 207 915 7869
E-Mail: jasmine.malone@frost.com